Research studies

Patient studies

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Purpose:  Post-marketing safety data on patients treated and untreated with eculizumab

Principal
investigator:

Anne King, MD
 Sponsor: Alexion Pharmaceuticals Inc. 
 Trial no.: NCT01522183
 Contact:

Mary Baldecchi (mary.baldecchi@vcuhealth.org) 

Transplant Patient Registry of Liver, Kidney and/or Pancreas

Purpose: This is a registry of data collected from patient records, both of those who have a condition which may require transplantation and those who have undergone transplantation of the liver, kidney, and/or pancreas.
Principal investigator: Adrian Cotterell, MD
Sponsor: VCU Research
Trial no.: NCT00238693
Contact: Mary Baldecchi (mary.baldecchi@vcuhealth.org)

CITR: Collaborative Islet Transplant Registry

Purpose: To expedite progress and promote safety in islet/beta cell transplantation through the collection, analysis, and communication of comprehensive and current data on all islet/beta cell transplants performed in North America, as well as some European and Australian centers. 
Principal investigator: Marlon Levy, MD 
Sponsor: Emmes
Trial no.: N/A (CITR Website) 
Contact: Mary Baldecchi (mary.baldecchi@vcuhealth.org) 

Translational Studies

Effect of NF1 loss-of-function mutation on the development and metastasis of human hepatocellular cancer

Purpose: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the 5th most common cancer worldwide. Unlike most cancers whose incidences have plateaued or are decreasing, the rates of HCC have been steadily increasing. In the United States alone, the incidence of HCC has almost tripled over the last two decades and death from Hepatitis C related HCC is now the fastest rising cause of cancer related deaths in the United States.  Populations of patients suffering from chronic liver disease are especially at risk for the development of HCC, especially patients with viral hepatitis. Surgery, either resection or transplantation, is currently the only potential curative therapy for patients with large HCCs.  We aim to develop therapies to ameliorate the development of HCC.
Principle investigator: Trevor Reichman
Contact: trevor.reichman@vcuhealth.org